

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE SENATE
05 AUG -9 AM 10:38

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Wheat Government Relations			
2. Address <input type="checkbox"/> Check if different than previously reported 1201 South Eads Street Suite Two Arlington VA 22202 USA			
3. Principal place of business (if different than line 2) City _____ State/Zip or Country _____			
4a. Contact Name Mr. Alan Wheat	b. Telephone number 703-271-8770	c. E-mail awheat@wheatgr.com	5. Senate ID # 47198-428
7. Client Name <input type="checkbox"/> Self GlaxoSmithKline	6. House ID # 34397030		

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 3)

9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activity **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>40,000</u>	\$10,000 or more <input type="checkbox"/> ⇨ \$ _____
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expert accounting method. See instructions for description of options.
	<input type="checkbox"/> Method A. Reporting amounts using LDA definitions on
	<input type="checkbox"/> Method B. Reporting amounts under section 6053(b)(8) Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Internal Revenue Code

Edit >

Signature _____

Date _____

Printed Name and Title Alan Wheat, President

Registrant Name Wheat Government Relations Client Name GlaxoSmithKline

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

HR 3010 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006
 H.R.2744 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006
 Drug Importation
 AIDS Drug Assistance Program


17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
 Senate

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Alan	Wheat	
Julie	Shroyer	
Steve	Dye	
MaryAnne	Sapio	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date _____

Printed Name and Title Alan Wheat, President

Registrant Name Wheat Government Relations Client Name GlaxoSmithKline

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

H.R.328 - Pharmaceutical Market Access Act of 2005
 S.109 - Pharmaceutical Market Access Act of 2005
 H.R.700 - Pharmaceutical Market Access and Drug Safety Act of 2005
 S.334 - Pharmaceutical Market Access and Drug Safety Act of 2005

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
 Senate

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Alan	Wheat	
Julie	Shroyer	
Steve	Dye	
MaryAnne	Sapio	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Printed Name and Title Alan Wheat, President

